NCT07446322 FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Status RECRUITING Phase PHASE2
NCT07280377 A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05519059 Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer Status COMPLETED Phase PHASE1
NCT05514990 Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04445844 INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04215146 A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04102618 A Window-of-opportunity Study of Pelareorep in Early Breast Cancer Status TERMINATED Phase EARLY_PHASE1
NCT03605719 Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT02101944 Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT01199263 Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Status COMPLETED Phase PHASE2